论文部分内容阅读
目的观察低分子肝素钙治疗进展性脑梗死的临床疗效及神经功能缺损评分。方法 64例进展性脑梗死患者随机分为治疗组33例,对照组31例,两组均采用常规治疗,治疗组在对照组的基础上加用低分子肝素钙0.4ml/Q12h腹壁皮下注射连用5～7d,治疗前及治疗后1周、2周观察临床疗效及神经功能缺损评分。结果治疗后两组神经功能缺损评分均有所减低,但治疗组神经功能缺损评分比较而言要显著低于对照组。结论低分子肝素钙在治疗进展性脑梗死方面临床疗效显著,同时能帮助缺血后神经功能缺损恢复,且整个治疗过程安全有效。
Objective To observe the clinical curative effect and neurological deficit score of low molecular weight heparin in patients with progressive cerebral infarction. Methods Sixty-four patients with progressive cerebral infarction were randomly divided into treatment group (n = 33) and control group (n = 31). Both groups were treated by conventional therapy. The treatment group was given subcutaneous injection of low molecular weight heparin 0.4ml / Q12h on the basis of control group 5 ~ 7d, before treatment and after treatment for 1 week, 2 weeks to observe the clinical efficacy and neurological deficit score. Results After treatment, the score of neurological deficit in both groups decreased, but the score of neurological deficit in the treatment group was significantly lower than that of the control group. Conclusion The low molecular weight heparin in the treatment of progressive cerebral infarction clinical efficacy significantly, at the same time can help post-ischemic neurological deficit recovery, and the entire course of treatment is safe and effective.